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Dementia with Lewy bodies (DLB) is the second leading cause of dementia following
Alzheimer’s disease (AD) and accounts for up to 25% of all dementia. DLB is distinct from
AD in that it involves extensive neuropsychiatric symptoms as well as motor symptoms,
leads to enormous societal costs in terms of direct medical care and is associated with
high financial and caregiver costs. Although, there are no disease-modifying therapies
for DLB, we review several new therapeutic directions in treating DLB. We discuss
progress in strategies to decrease the level of alpha-synuclein, to prevent the cell to cell
transmission of misfolded alpha-synuclein, and the potential of brain stimulation in DLB.
Keywords: Dementia with Lewy Bodies, Parkinson’s disease, Alzheimer’s disease, Deep Brain Stimulation,
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Introduction
Dementia with Lewy bodies (DLB) is the second most common pathologic diagnosis of dementia,
following Alzheimer’s disease (AD), comprising 25% of all dementias (Heidebrink, 2002; Mayo and
Bordelon, 2014). Yet, DLB is underdiagnosed (Galvin and Balasubramaniam, 2013). The pathologic
feature of DLB is the presence of Lewy bodies in the cortex and brainstem. Lewy-bodies are
neuronal inclusions of abnormal filamentous assemblies of α-synuclein and ubiquitin (Spillantini
et al., 1998). DLB is associated with high burdens of neurofibrillary tangles (Merdes et al., 2003) but
lower levels of amyloid-β (Masliah et al., 2001).
DLB is characterized by fluctuating cognition and alertness, visual hallucinations, parkinsonian
movement syndrome, REM sleep disorders, neuroleptic sensitivity, and reduced striatal dopamine.
Due to the neuropsychiatric features of DLB, the costs for care of DLB patients is more than 2 times
higher than AD patients (Bostrom et al., 2007; Ricci et al., 2009).
It is very difficult to distinguish DLB from dementia-associated with Parkinson’s disease (PDD),
which shares many underlying clinical and pathological features with DLB (Narayanan et al., 2013;
Parker et al., 2013). Current guidelines arbitrarily distinguish DLB and PDD by the timing of onset
of dementia in relation to motor symptoms (Lippa et al., 2007). One influential hypothesis is that
synuclein spreads rostrally from the periphery (Braak et al., 2003). However, this hypothesis does
not account for widespread cortical synuclein observed at initial diagnosis DLB.
Abbreviations: AD, Alzheimer’s disease; BFCN, Basal forebrain cholinergic neurons; DBS, Deep brain stimulation; DLB,
Dementia with Lewy bodies; NBM, nucleus basalis of Meynert; PDD, dementia-associated with Parkinson’s disease; PD,
Parkinson’s disease; RNAi, RNA interference.
Zhang et al. DLB therapies
Targeting α-synuclein
The major component of Lewy bodies in DLB and Parkinson’s
disease (PD) is misfolded α-synuclein (Spillantini et al., 1998).
The normal α-synuclein is a soluble protein and is involved
in presynaptic processing of neurotransmitters, mitochondrial
function and proteasome processing (Cheng et al., 2011). In
DLB and PD, α-synuclein aggregates in Lewy bodies and
causes neuronal death. The α-synuclein gene triplication and
missense mutations, E46K and A53T, are associated with
familial PD/PDD/DLB. Overexpression of human wild-type α-
synuclein in mice leads to early cholinergic deficits and cognitive
abnormalities, which appears before the development of motor
deficits (Magen et al., 2012). Importantly, α-synuclein knockout
mice have normal neuroanatomy (Abeliovich et al., 2000),
normal movement (Kokhan et al., 2012) and normal learning
behavior (Chen et al., 2002). Therefore, various strategies have
been employed to reduce α-synuclein directly for the treatment
of DLB and PD.
Nilotinib is an Abl tyrosine kinase inhibitor approved by
FDA for the treatment of chronic myelogenous leukemia.
Nilotinib decreased the level of α-synuclein and reverse the
loss of dopamine neurons in a mouse model overexpressing
A35T mutant α-synuclein (Hebron et al., 2013). It was also
shown that the Abl inhibition through nilotinib promotes
autophagic degradation of α-synuclein. Another study has
shown that α-synuclein is a substrate of Abl and Abl directed
phosphorylation leads to decreased α-synuclein degradation
through the autophagy and proteasome pathways (Mahul-
Mellier et al., 2014). A Phase I clinical trial of nilotinib is currently
ongoing (http://clinicaltrials.gov/).
Secreted, extracellular α-synuclein might play a crucial role
in the passage of misfolded α-synuclein from one cell to
another (Lee et al., 2014). Therefore, immunotherapy targeting
extracellular α-synuclein has been proposed (Masliah et al., 2005,
2011; Valera and Masliah, 2013). Masliah et al. (2011) found
that immunization with recombinant human α-synuclein led to
a reduction in α-synuclein accumulation and neurodegeneration
without neuroinflammation. With promising results from active
immunization, they then applied passive immunization to the
same mouse model using 9E4, an antibody targeting the C
terminal epitopes of α-synuclein. They found that 9E4 reduced
the accumulation of α-synuclein aggregates in neocortex and
hippocampus. They also found that 9E4 treatment ameliorated
motor behavior and learning deficits, and improved synaptic
pathology. Bae et al. (2012) found that administration of anti-
α-synuclein antibody into the brains of PGDF-α-synuclein
transgenic mice prevented cell-to-cell transmission of α-
synuclein. The antibodies aid in clearance of extracellular α-
synuclein proteins by microglia, thereby preventing their actions
on neighboring cells. Misfolded extracellular α-synuclein might
interact with antibodies to form antigen-antibody complexes,
and these complexes are endocytosed and transferred to the
lysosomal compartment for degradation through autophagy
(Masliah et al., 2011). Antibody bound extracellular α-synuclein
aggregates are also cleared by microglia cells (Bae et al., 2012).
Tran et al. (2014) employed an antibody specific for misfolded
α-synuclein and obtained promising results in animal models as
well. Recently, AFFiRiS AG, an Austria-based biotech company,
developed a vaccine targeting PD and other synucleinopathies.
The peptides used in the vaccine are designed to be too
small to induce an α-synuclein-specific T cell response, thus
avoiding T cell autoimmunity (Mandler et al., 2014). The
vaccine was tested in the PGDF-α-synuclein and the Thy1-α-
synuclein transgenic mouse models. Active vaccination resulted
in decreased accumulation of α-synuclein oligomers in axons
and synapses, reduced neurodegeneration, and improvements in
motor and memory deficits in both models. Phase I clinical trials
are currently ongoing in early PD and multiple-system atrophy
patients with PD01A and PD03A vaccines (http://clinicaltrials.
gov/).
Another strategy targeting α-synuclein is RNA interference
(RNAi) (Fire et al., 1998). Direct infusion of siRNA led to the
reduction of α-synuclein (Lewis et al., 2008; McCormack et al.,
2010). Recent studies have employed virally-mediated RNAi
delivery. Sapru et al. (2006) used lentivirus-mediated RNAi to
successfully silence human α-synuclein expression in the rat
substantia nigra. Khodr et al. employed AAV-mediated RNAi,
but found that this approach caused neurotoxicity (Han et al.,
2011; Khodr et al., 2011, 2014). They then tried AAV-mediated
RNAi embedded in mircoRNA30 backbone, and they were able
to reverse α-synuclein induced forelimb deficit and dopaminergic
neuron loss. However, this approach induced inflammation.
Transgene delivery using AAV was shown to be safe in previous
studies and this technology has been used in human clinical trials
in PD (LeWitt et al., 2011).
Other approaches employed to reduce α-synuclein include
ribozymes (Hayashita-Kinoh et al., 2006), intracellular
expression of single chain antibodies (Zhou et al., 2004; Lynch
et al., 2008; Yuan and Sierks, 2009), endogenous microRNA
(Junn et al., 2009), and mirtrons (Sibley et al., 2012). A safe and
effective approach to reduce the level of α-synuclein will likely
slow down or even reverse the progression of DLB.
Targeting Synucleinopathy Progression
α-synuclein spreads via prion-like mechanisms (Angot et al.,
2010). Initial evidence came from postmortem PD brains who
received transplants of fetal mesencephalic neurons over 10 years
before death. Two studies independently found Lewy bodies
in grafted neurons (Kordower et al., 2008; Li et al., 2008).
Further, studies in animal models have confirmed the prion-
like spreading synucleinopathy (Desplats et al., 2009; Hansen
et al., 2011; Kordower et al., 2011; Volpicelli-Daley et al., 2011;
Angot et al., 2012; Luk et al., 2012a,b; Mougenot et al., 2012;
Masuda-Suzukake et al., 2013; Rey et al., 2013; Sacino et al., 2013;
Reyes et al., 2014). Interestingly, recent studies have shown that
brain extracts from multiple-system atrophy and PD patients
triggered α-synuclein pathology in animal models (Watts et al.,
2013; Recasens et al., 2014), in a way similar to the transmission
of kuru disease to chimpanzees.
As shown in Figure 1, the development/progression of
α-synuclein pathology consists of the following steps: (1)
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FIGURE 1 | Prion-like progression of synucleinopathy. Endogenous
α-synuclein misfolds and forms amyloid fibrils. α-synuclein amyloid fibrils that
fail to be cleared act as seeds and convert more endogenous α-synuclein
into misfolded amyloid fibrils. Through intracellular axonal transport,
misfolded α-synuclein fibrils undergo long distance travel within the nervous
system. Misfolded α-synuclein fibrils might be released by exocytosis or in
exosomes. Misfolded α-synuclein can then be taken up by surrounding
neurons, through endocytosis or direct fusion with exosomes. Misfolded
α-synuclein fibrils taken up by surrounding neurons can recruit endogenous
α-synuclein to form more amyloid fibrils, through the seeding mechanism.
misfolding/aggregation of α-synuclein, (2) induction of
endogenous α-synuclein to form more aggregates by the
misfolded α-synuclein aggregates (also known as “seeding”),
(3) long distance transport of α-synuclein aggregates,
(4) secretion/exocytosis of α-synuclein aggregates, (5)
uptake/endocytosis of α-synuclein aggregates by surrounding
neurons, (6) formation of more α-synuclein aggregates through
“seeding” in the healthy neuron. Extensive studies have been
performed to determine the details of each step, and potential
therapeutic approaches are being developed to target the
prion-like progression of synucleinopathy.
In vitro studies have shown that under certain conditions,
recombinant α-synuclein forms amyloid fibrils spontaneously
(Narkiewicz et al., 2014). Addition of small amount (0.001%)
of preformed α-synuclein fibrils to unfolded recombinant α-
synuclein solution could accelerate the formation of more fibrils,
and this phenomenon is known as seeding (Wood et al.,
1999). Strikingly, intrastriatal inoculation of recombinant α-
synuclein fibrils in wild type mice led to Lewy pathology
in anatomically interconnected regions (Luk et al., 2012a).
Agents preventing the formation of α-synuclein fibrils or
interfering with the seeding process could potentially serve
as disease modifying treatments for both DLB and PDD.
Efficient in vitro screening approaches and chronically α-
synuclein “infected” cell lines have been established (Herva et al.,
2014; Narkiewicz et al., 2014). These should allow for high-
throughput screening of compounds targeting synucleinopathy
(Rochet, 2007). Several agents targeting α-synuclein aggregation
have been tested in cellular or animal models with promising
results (El-Agnaf et al., 2004; Jiang et al., 2010; Zhou
et al., 2011; Wagner et al., 2013). On the other hand,
avoiding environmental exposure to agents associated with
induction of synucleinopathy is very important (Elbaz et al.,
2009).
It is well established that α-synuclein is involved in vesicular
trafficking and release (Burre et al., 2010; Nemani et al., 2010),
and that it is transported along the axons (Jensen et al.,
1999; George et al., 2013). Importantly, recent cell culture
studies have utilized microfluidic chambers to separate neuronal
cell bodies from their terminals, and demonstrated that α-
synuclein fibrils can be transported along the axons in both
directions (Danzer et al., 2011; Volpicelli-Daley et al., 2011;
Freundt et al., 2012). Freundt et al. (2012) used live-cell
imaging and immunofluorescence, and confirmed the axonal
transport of fluorescent α-synuclein fibrils, and their transfer
to second-order neurons through axon-to-soma transfer. In
order to confirm the long distance transport of misfolded
α-synuclein in a synucleinopathy mouse model induced by
intragastric administration of rotenone, Pan-Montojo et al.
(2012) performed resection of the autonomic nerves and found
that the progression of synucleinopathy was blocked. These
results strongly indicate that the progression of synucleinopathy
is based on the transneuronal and axonal transport of misfolded
α-synuclein.
A prerequisite of cell to cell transmission is the secretion and
uptake of α-synuclein fibrils. α-synuclein is present in human
plasma, cerebrospinal fluid, and brain interstitial fluid (Borghi
et al., 2000; El-Agnaf et al., 2003; Emmanouilidou et al., 2011).
α-synuclein that is in the CSF and brain interstitial fluid is
derived from CNS neurons (Mollenhauer et al., 2012), is present
in cytoplasmic vesicles and could be secreted through exocytosis
(Lee et al., 2005; Jang et al., 2010). Exocytosis of α-synuclein and
translocation of α-synuclein into vesicles increases under various
stress conditions (Jang et al., 2010). Intravesicular α-synuclein
was found to be more prone to aggregation and aggregated forms
of α-synuclein are also secreted from cells (Lee et al., 2005).
Exocytosis of α-synuclein was found to be independent of the
ER-Golgi classical pathway, and exosome-associated exocytosis
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has been implicated in the release of misfolded α-synuclein and
the cell-to-cell transmission of synucleinopathy (Lee et al., 2005;
Emmanouilidou et al., 2010). Exosome-associated exocytosis was
thought to be directed by the multivesicular bodies–intraluminal
vesicles mediated pathway (Emmanouilidou et al., 2010). In
addition to exocytosis, the multivesicular bodies–intraluminal
vesicles pathway also goes toward lysosomal degradation. It
has been found that lysosomal dysfunction increases exosome-
associated α-synuclein release and transmission (Alvarez-Erviti
et al., 2011). Interestingly, Hasegawa et al. (2011) found that
impaired biogenesis of multivesicular bodies was associated
with hyper-secretion of α-synuclein. α-synuclein could also be
released through the Rab11a-dependent recycling endosome
pathway, and the blockage of multivesicular bodies mediated
lysosomal degradation of α-synuclein could have contributed
to the hyper-secretion of α-synuclein (Liu et al., 2009). Once
released to the extracellular space, free misfolded α-synuclein
could get internalized by nearby neurons through endocytosis,
and exosome-associated α-synuclein could enter cytosol directly
by fusion of the exosome with the plasma membrane (Desplats
et al., 2009; Danzer et al., 2012). Immunotherapy approaches
targeting extracellular α-synuclein were discussed in the previous
section. Strategies targeting the exocytosis and endocytosis
processes are being considered, but these should be approached
with caution, as severe side effects might ensue (Lee et al., 2014).
In the meanwhile, other mechanisms have also been proposed for
the pathogenesis of DLB: mitochondrial dysfunction, abnormal
calcium handling, and altered inflammatory responses (Goedert
et al., 2013; Mullin and Schapira, 2013; Overk and Masliah, 2014;
Zaltieri et al., 2015). Also, it is important to note that some
studies have provided evidences that argue against the concept of
prion-like progression in synucleinopathy (Hallett et al., 2014).
Deep Brain Stimulation
In addition to α-synuclein centered approaches, very recently,
much attention has been attracted to another highly promising
approach: Deep Brain Stimulation. Deep brain stimulation (DBS)
has been approved by the FDA for the treatment of PD (Deuschl
et al., 2006; Follett et al., 2010), essential tremor, dystonia, and
obsessive-compulsive disorder (Rezai et al., 2008). It has been
employed in research studies to treat chronic pain and major
depressive disorder (Plow et al., 2012; Blumberger et al., 2013).
Recently, DBS has been proposed in the treatment of cognitive
disorders like AD (Sankar et al., 2014). Currently, two Phase I
clinical studies are being conducted for the treatment of DLB
with DBS targeting the nucleus basalis of Meynert (NBM) (http://
clinicaltrials.gov/). Here, we review DBS approaches that are
directly and indirectly related to treating DLB.
DBS has the potential to modulate cognition. In PDD patient,
Freund et al. (2009) and Barnikol et al. (2010) performed DBS
targeting the NBM, a cholinergic nucleus. They found markedly
improved cognition. This is the first and only published study
targeting synucleinopathy associated dementia with DBS. This
PDD patient received bilateral implantation of DBS leads into
the STN and NBM. While isolated STN stimulation led to motor
improvement without significant change in cognitive function,
the addition of NBM stimulation is associated with improvement
in cognitive functions. NBM stimulation also led to significant
improvement in personality features, social communication, and
overall quality of life. The authors believe that these effects were
likely related to the effects of stimulating residual cholinergic
projections and cell bodies in NBM. At this point, it is not
clear whether DBS in NBM influences the progression of PDD
or DLB, but two disease modifying mechanisms have been
proposed based on preclinical studies. These include increased
nerve growth factor (NGF) secretion and enhanced neurogenesis
(Hotta et al., 2009; Jeong Da et al., 2014) (Figure 2). In terms of
short term effects of NBM DBS, animal studies have indicated
that NBM DBS is linked to brain plasticity and cortical map
reorganization(Kilgard and Merzenich, 1998), and associated
with enhanced learning and induction of immediate-early gene
c-Fos (Boix-Trelis et al., 2006, 2009).
Basal forebrain cholinergic neurons (BFCN), consisting of
NBM, medial septum and diagonal band of Broca, provide
cholinergic innervations to the neocortex, entorhinal cortex and
hippocampus. It has been found that NGF is very important
for the survival and function of BFCN, and it has been shown
that the majority of NGF nurturing BFCN comes from targeting
areas of BFCN (neocortex, entorhinal cortex, and hippocampus)
and is transported retrogradely through the axons back to the
cell bodies of BFCN (Isacson et al., 2002). Interestingly, NBM
DBS led to increased NGF secretion in wild type rats (Hotta
et al., 2007, 2009), indicating that DBS could potentially reverse
BFCN degeneration through increasing NGF trophic support. In
another study, Jeong Da et al. (2014) injected 192 IgG-saporins
intraventricularly to induce cholinergic lesion in rats. They found
that DBS in the medial septum restores spatial memory in the
setting of cholinergic neuron damage, and that this effect is
FIGURE 2 | Deep Brain Stimulation (DBS) of Nucleus Basalis of Meynert
(NBM) in Dementia with Lewy Bodies (DLB). NBM is one group of the
basal forebrain cholinergic neurons (BFCN). The degeneration of BFCN is
associated with decreased cholinergic tone and cognitive deficits in DLB. NBM
provides cholinergic innervations to the entire neocortex. DBS of NBM likely
enhances the cholinergic tone of neocortex, leading to improved cognitive
function and quality of life. Potential disease modifying mechanisms include
enhanced neurogenesis and increased nerve growth factor trophic support.
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associated with an increase in hippocampal cholinergic activity
and neurogenesis.
NBM DBS was first applied to an AD patient three decades
ago (Turnbull et al., 1985). Turnbull et al. applied cyclic
DBS to the left NBM for 9 months, and glucose utilization
was relatively preserved in the left cerebral hemisphere of
this AD patient. However, DBS did not lead to clinical
improvement on memory or other cognitive measures. Recently,
Kuhn et al. (2015) performed a Phase I clinical trial of
NBM DBS on 6 mild to moderate AD patients. No safety
concern was noted, and promising positive effects were
observed on cognitive parameters including Alzheimer’s Disease
Assessment Scale-Cognitive subscale and Mini Mental Status
Exam, global functioning as measured by Clinical Dementia
Rating, subjectively perceived quality of life, and increased
cortical glucose metabolism (via PET).
DBS targeting fornix, part of the Papez circuit which is very
important in memory retention, has also been tested in AD
patients, with promising results (Laxton et al., 2010). A Phase
II clinical trial of Fornix DBS is currently underway in AD
patients. Studies on human subjects have also indicated that DBS
of entorhinal cortex (Suthana et al., 2012), anterior thalamic
nucleus (Oh et al., 2012), pedunculopontine tegmental nucleus
(Stefani et al., 2010), rhinal cortex and hippocampus (Fell et al.,
2013) might also enhance memory and cognitive functions.
Animal studies with DBS targeting fornix (Hescham et al., 2013),
entorhinal cortex (Stone et al., 2011), anterior thalamic nucleus
(Hamani et al., 2011; Chen et al., 2014) and hippocampus (Berger
et al., 2011) have also indicated positive effects on memory and
cognitive functions.
Animal studies have targeted other areas of the brain and
evaluated the effects of DBS on cognitive functions (Hardenacke
et al., 2013). Promising results were obtained through DBS
targeting anterior caudate nucleus (Williams and Eskandar,
2006), midline thalamic nuclei (Arrieta-Cruz et al., 2010), central
thalamus (Shirvalkar et al., 2006; Mair and Hembrook, 2008;
Shah et al., 2009; Smith et al., 2009), lateral hypothalamus
(Soriano-Mas et al., 2005, 2007; Ruiz-Medina et al., 2008a,b;
Huguet et al., 2009; Aldavert-Vera et al., 2013), and amygdala
(Kadar et al., 2011).
Given its low complication rate and reversibility (Deuschl
et al., 2006; Voges et al., 2006), DBS seems to be a safe and
promising approach in DLB management. Though long term
disease modifying profile is not clear at this point, DBS will
likely improve short term cognitive functions, and importantly,
the quality of life of patients with DLB and PDD (Freund
et al., 2009). Though DBS targeting fornix has attracted much
attention in the field of AD treatment, NBM DBS currently
holds the most promise for DLB patients. Unlike AD, which
usually presents with memory deficits, DLB usually presents
with fluctuating cognition and visuospatial deficits with relative
sparing of memory in earlier stages (Mayo and Bordelon, 2014).
While waiting for the results of ongoing clinical trials, it is
worth noting that no DBS studies have been performed on
animal models of dementia associated with synucleinopathy.
These preclinical studies will likely accelerate and validate clinical
application of DBS in DLB and other synucleinopathy associated
dementia.
Conclusion
DLB is the second leading cause of dementia following AD,
and disease modifying therapies are urgently needed. Significant
progress has been made in the past decade regarding the
underlying mechanism of DLB pathogenesis. Future therapies
might modify the progression of DLB by targeting α-synuclein
or by stimulating deep brain structures. Cutting edge research
into the basic mechanism of DLB pathogenesis and preclinical
studies testing novel therapies will continue to play crucial
roles in the development of disease modifying treatments
for DLB.
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